Tuesday morning, Sears Holding (SHLD) released a bit of good and a bit of bad news. Let's start with the bad news.

The retailer announced that its same-store sales dropped 1.7% during December. The company's eponymous Sears stores saw December same-store sales fall 6%, more than offsetting Kmart's 2% growth. The firm blamed the sales drop at Sears on a major decline in sales of consumer electronics, along with appliances and tools.

A parade of retailers have stepped up Thursday morning to unveil their December sales results, including The Gap Inc. (GPS). The jeans giant confessed to an unexpected 3% decline in same-store sales for the month, falling well short of analysts' expectations for an increase of 2.6%.

Gap North America was hit hardest, with same-store sales tumbling 8% for the month. The only business segment to record a gain for December was Banana Republic North America, as same-store sales improved 1%.

Nasdaq OMX Group (NDAQ) is lingering near annual-high territory, but not everyone on Wall Street is impressed with the stock's price action. Bright and early Tuesday morning, the exchange operator was singled out for a bearishly biased options strategy.

Shortly after the opening bell, a block of 1,950 March 24 puts traded near the ask price at $1.20, indicating they were most likely purchased. At the same time, a block of 3,900 March 21 puts changed hands near the bid price at $0.30, suggesting they were probably sold. Volume is easily outstripping open interest at both strikes, so it's safe to assume that we're seeing the initiation of a new spread position.

Las Vegas Sands (LVS) gapped higher out of the gate Monday morning, as traders cheered the latest round of data from Macau. Casino revenues in the popular gambling destination rose 58% in 2010 to a record 188.34 billion patacas, or roughly $23.51 billion, according to the Macau Gaming Inspection and Coordination Bureau.

Revenue for the month of December ballooned 66.4% to an all-time monthly high of 18.883 billion patacas, or approximately $2.36 billion.

Shares of Anadarko Petroleum (APC) gapped higher right out of the gate Thursday morning, thanks to a report that BHP Billiton (BHP) may be eyeing the firm as a potential takeover target. According to the U.K.'s Daily Mail, BHP could be prepping an offer worth $90 per share to acquire Anadarko. However, neither company has issued a formal response to the speculation.

After jumping to a new annual high of $76.50 bright and early Thursday morning, APC is on pace to notch a weekly finish atop the $70 level for the first time since April 23. In fact, if the shares can maintain their positive momentum through Friday's close, the shares could stage their first weekly victory north of $75 since June 2008.

Call volume is unusually heavy on Advanced Micro Devices (AMD) today, with nearly 8,300 contracts changing hands during the first hour of the session -- easily outpacing the stock's average daily call activity of 6,774 contracts. However, the day's option volume isn't necessarily bullish in nature.

Nearly all of today's volume has taken place at AMD's January 2012 7.50 call, where a block of 8,000 contracts traded at the bid price -- suggesting they were most likely sold. This block appears to have been tied to a corresponding stock trade, which means we're likely seeing the initiation of a buy-write position.

Options players rushed to place their bets on The Gap (GPS) Tuesday, with volume rising to five times the norm within the first hour of trading. Taking a closer look at the major block trades, it looks as though one speculator is anticipating a major price swing from GPS during the next year.

Specifically, the trader opened a long strangle on GPS by purchasing 2,619 January 2012 20-strike calls, and simultaneously buying 2,619 January 2012 17.50 puts. This two-legged option strategy allows the trader to benefit from a drastic move in the underlying equity, regardless of whether the shares move higher or lower.

Pharmaceutical company MannKind (MNKD) shares have traded considerably higher this morning, gaining 9% shortly after the opening bell and trading in the upper $8 region. It appears that the rally was sparked by news that the U.S. Federal Drug Administration would not be able to complete a review of the company's inhaled insulin Afrezza by December 29.

The FDA added that it will need roughly four more weeks to complete the review. Back in July, the FDA accepted a resubmission on Afrezza and classified it a class 2 response.

Monday morning, Amazon.com (AMZN) announced that the third-generation Kindle is now its best-selling product of all time, unseating former title-holder Harry Potter and the Deathly Hallows. Amazon didn't provide specific sales figures for the e-reader, but the retail giant added that more Kindle books were purchased this past Christmas Day than on any other day in history -- confirming that the gadgets are quite a popular gift.

Meanwhile, Nov. 29 -- or "Cyber Monday" -- was the peak day for holiday shopping on Amazon. More than 13.7 million items were ordered worldwide on the Monday after Thanksgiving, which translates to about 158 items per second.

We may soon see "one of the biggest advances in years in the technology that powers laptop and desktop computers," according to the Wall Street Journal, as chipmakers begin to merge microprocessors and graphics-processing units.

Microprocessors are described as "the calculating engines that run most PC software," while graphics-processing units "render images in video games and other programs." According to the report, Intel (INTC) and Advanced Micro Devices (AMD) are expected to make announcements about this move at the upcoming Consumer Electronics Show.

Thursday morning, GPS specialist Garmin Ltd. (GRMN) said it lost a patent dispute with Japanese firm Pioneer Corp. The District Court of Dusseldorf in Germany found that two patents owned by Pioneer were infringed by a certain functionality in Garmin's software.

However, Garmin says it has already worked out "minor software revisions that eliminate the narrow functionality at issue in the litigation." As a result, the company doesn't expect any significant impact on its ability to import and sell its navigational products.

Shares of Cumberland Pharmaceuticals (CPIX) are having a rough go of it after the Food and Drug Administration (FDA) outlined some concerns that will further delay a ruling on its liver drug. The regulatory agency already postponed its decision from August to December, and now the FDA says it needs additional data before it can recommend the drug for approval.

In its complete response letter to Cumberland, the FDA noted insufficient evidence to prove that the injectable drug, Acetadote, is effective in all patients. Cumberland said it plans to meet with the FDA soon to address the outstanding issues.

Hovnanian Enterprises (HOV) announced Tuesday that its fourth-quarter loss checked in at $1.68 per share ($132.1 million). While these results were better than a year ago when the company reported a loss of $3.21 per share ($250.8 million), the homebuilder fell short of the consensus estimate of a loss of 91 cents per share. Quarterly revenue checked in at $353 million, which is far worse than the $437.4 million a year earlier. The amount of contracts for homes fell 13%, coming in at 1,078 homes.

Shares of Netflix (NFLX) started Tuesday on a high note, with the shares gaining more than 1% out of the gate. Traders appear to be responding to new comments from Jim Cramer, after the host of CNBC's Mad Money offered an upbeat opinion on the stock Monday.

Specifically, Cramer is enthusiastic about Netflix's push into streaming content, and he has high expectations for future subscriber growth. The analyst also argued that the stock's valuation is actually quite reasonable, when measured against the company's long-term growth rate. For traders looking to take part in continued gains by NFLX, Cramer suggested in-the-money call options.